Celldex Therapeutics traded at $36.66 this Monday December 5th, decreasing $0.68 or 1.82 percent since the previous trading session. Looking back, over the last four weeks, Celldex Therapeutics lost 5.19 percent. Over the last 12 months, its price rose by 0.66 percent. Looking ahead, we forecast Celldex Therapeutics to be priced at 36.13 by the end of this quarter and at 32.73 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 163.94 0.28 0.17% 35.10%
Agenus 2.79 -0.18 -6.06% -7.92%
Applied Genetic Technologies 0.39 0.005 1.23% -81.08%
Amgen 284.91 -0.60 -0.21% 36.46%
Aptinyx Inc 0.25 -0.01 -3.47% -88.48%
Biocept 0.76 0.0001 0.01% -79.46%
Bristol-Myers Squibb 80.70 -0.43 -0.53% 42.00%
Celldex Therapeutics 36.66 -0.68 -1.82% 0.66%
CytrRx Corporation 0.17 -0.01 -2.86% -66.00%
Glaxosmithkline 35.16 -0.19 -0.54% -15.80%
Immunogen 5.43 -0.04 -0.73% -18.83%
Merrimack Pharmaceuticals 11.85 -0.03 -0.25% 189.02%
Nektar Therapeutics 2.97 -0.08 -2.62% -74.96%
Lumos Pharma Inc. 5.17 0.02 0.39% -24.42%
Northwest Biotherapeutics 1.00 0.08 8.70% 32.47%
Pfizer 50.73 -0.18 -0.35% -1.46%
Rigel Pharmaceuticals 0.95 0.12 13.98% -61.54%
Roche Holding 308.15 -0.10 -0.03% -16.16%
Seattle Genetics 121.22 -1.19 -0.97% -16.98%

Indexes Price Day Year
USND 11240 -221.56 -1.93% -26.18%
US2000 1840 -52.62 -2.78% -16.49%

Celldex Therapeutics
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutic monoclonal and bispecific antibodies. The Company's drug candidates include antibody-based therapeutics to improve the lives of patients with inflammatory diseases and many forms of cancer. The Company is engaged in the research and development of CDX-015, CDX-1140 and CDX-527. CDX-0159, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, has completed a Phase Ia study in healthy subjects. CDX-1140, an agonist monoclonal antibody targeted to CD40, a key activator of immune response, is being studied in a Phase I study. CDX-527 is the first candidate from Celldex's bispecific antibody platform. CDX-527 is a bispecific antibody that uses the Company's anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, and Company has initiated a Phase I study in advanced solid tumors.